Tue, November 30, 2021


Human trials start for Chinas new COVID-19 vaccine

BEIJING - Sinopharm, the Chinese pharmaceutical giant, has commenced phase-1 and phase-2 clinical trials for its new recombinant vaccine against COVID-19 in central Chinas Henan province.

Developed by the China National Biotec Group (CNBG), a Sinopharm's bioscience subsidiary, the vaccine was issued with a clinical research permit from the National Medical Products Administration on April 9.

This is the CNBG's third COVID-19 vaccine candidate approved for human trials.

Researchers started the early-staged clinical trials in the city of Shangqiu, Henan Province. The trials were randomized, double-blind and placebo-controlled, according to a company statement.

Zhang Yuntao, vice president of the CNBG, said the recombinant vaccine candidate has been genetically engineered. Unlike the company's inactivated COVID-19 vaccines, the new one does not need a high-grade biosafety laboratory for manufacture, and it can quickly achieve large-scale production.

"It is designed for people aged three and above," Zhang said.

Whether the gene recombinant vaccine should be administered in three doses will be determined by the results of clinical trials, Zhang added.

Published : April 26, 2021

By : China Daily/ANN